（进博故事）从“进博宝宝”到“六边形战士”

Core Insights - Sanofi's Dupilumab injection (Dupixent®) has evolved significantly over seven years, expanding its indications and demonstrating the rapid pace of innovation in China [1][3][4] Group 1: Product Evolution - Dupilumab has transitioned from being recognized primarily for atopic dermatitis to covering seven indications, including respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) [3][4] - The drug's approval timeline in China has been notably faster than in the US and EU, showcasing "China speed" in regulatory processes [3] Group 2: Market Engagement - Sanofi has participated in the China International Import Expo (CIIE) for seven consecutive years, using the platform to enhance disease awareness and educate both the public and healthcare professionals [2][5] - The company has established a comprehensive value chain in China, including R&D, manufacturing, and commercial operations, reflecting its long-term commitment to the market [4] Group 3: Strategic Partnerships - Sanofi has formed significant collaborations with local partners, such as Shanghai Pharmaceuticals and KKR, to strengthen the pharmaceutical ecosystem in China [4] - The establishment of the Sanofi-KKR Innovation Fund, with a scale of approximately 2 billion yuan, aims to invest in innovative drug pipelines that have entered clinical stages in China [4]